Stocks on Tech Trader

Summary: Recent price action shows continued downside pressure with no clear reversal, despite solid fundamentals and raised guidance, so staying out avoids unnecessary risk in this choppy environment. ...

Summary: TMO just sold off sharply today after our exit yesterday, extending the downtrend with no reversal signals or positive catalysts to justify re-entry right now. ...

Summary: Recent breakdown below key support on heavy volume has erased gains from the post-earnings bounce, leaving the position underwater with no clear near-term catalyst strong enough to justify holding through potential further chop. ...

Summary: TMO holds above critical support with the May 20 Investor Day as a near-term catalyst and fresh positive momentum from raised guidance outweighing recent consolidation. ...

Summary: TMO holds above key support with the May 20 Investor Day as a clear near-term catalyst and fresh positive product momentum outweighing recent consolidation. ...

Summary: TMO is holding above post-earnings lows with the May 20 Investor Day still providing a clear near-term catalyst and no fresh negatives to derail momentum. Recent price action shows consolidation in the 462-475 range after the initial drop, but volume has been light and analysts remain bullish with targets well above current levels. The position entered at 468.04 is only modestly positive, yet the setup favors patience through the event rather than exiting early and risking a whipsaw if sentiment improves. Broader sector rotation mentions exist but don't override TMO's solid fundamentals and upcoming visibility.

Summary: TMO is holding steady above the post-earnings lows with improving momentum and the May 20 Investor Day just ahead as a solid near-term catalyst. ...

Summary: TMO is holding steady above recent lows on low volume after the post-earnings recovery, with the May 20 Investor Day and the $1.075B microbiology sale as clear near-term positives keeping the setup intact....

Summary: TMO is holding steady above recent lows on low volume after the post-earnings recovery, with the May 20 Investor Day and the $1.075B microbiology sale as clear near-term positives keeping the setup intact....

Summary: Price action shows TMO consolidating sideways right around our $468 entry after the post-earnings bounce to $479, with no major breakdown yet and low volume on the latest pullback suggesting limited selling pressure. Fundamentals remain solid with the Q1 beat, raised full-year guidance, the $1B+ microbiology sale freeing up capital, and the May 20 Investor Day as a clear near-term catalyst that could spark renewed buying. Analyst targets sit well above $600, implying substantial upside once direction clarifies, and we're only four days into the position with room to let it breathe toward that seven-day minimum hold. Exiting now risks missing the next leg higher in this recovery setup, especially since the broader downtrend from January highs appears to be finding support here.

Summary: ...

Summary: ...

Summary: ...

Summary: ...

Summary: ...

Summary: ...

Summary: ...

Summary: ...

Summary: ...

Summary: ...

Summary: ...

Summary: ...

Summary: ...

Summary: ...

Summary: ...

Summary: ...

Summary: ...

Summary: We're staying in cash for TMO right now at ~$489 on 4/7/26 after repeated losing long trades because the daily chart shows choppy consolidation in a larger downtrend from January highs with low volume and no clear breakout. ...

Summary: TMO is in a clear downtrend from January's $644 high to current ~$485 levels with repeated failed bounces and mostly losing long trades in our history, so staying in cash avoids risk ahead of April 23 earnings. ...

Summary: Exiting our long from $491.53 on 3/31 because TMO is stalling below the EMA near $498, closed weak off the day's highs on low volume, with stochastics overbought. ...

Summary: ...

Summary: ...

Summary: ...

Summary: ...

Summary: ...

Summary: ...

Summary: ...

Summary: TMO is rebounding with a strong up day to $482, building on our recent entry as oversold conditions improve and analyst targets remain well above $650....

Summary: ...

Summary: Although the downtrend and recent breakdown had us in cash, today's strong recovery from new lows at $458 to close up near $469 shows buyers defending the area and changes the short-term setup after three days of staying sidelined....

Summary: Following the downtrend assessment that led us to cash two days ago, today's breakdown to a new low at $462 with a weak close confirms the selling pressure remains dominant....

Summary: Building on the strong downtrend from $640 that prompted us to cash out yesterday, today's modest bounce to $473.54 lacks the volume and follow-through needed to change the bearish technical picture....

Summary: TMO is in a clear downtrend after collapsing from $640 in January to the $460s, with repeated failed bounces and our recent trade history showing consistent losses on longs. ...

Summary: Re-entering long one day after exit at much lower 469 vs 476 as extreme oversold RSI 25 signals bounce from broken supports, new March analyst buy ratings with $540-639 targets override prior layoff/sector concerns now digested. ...

Summary: Exiting long to cash as price breaks key support at 492 with accelerating downside momentum on high volume, oversold RSI failing to hold, and bearish MACD crossover amid layoff news and weak biotech sector sentiment....

Summary: Holding long as price tests rising support at 493 amid oversold RSI 32 and new bullish Bay Area expansions like cryo-EM center overriding layoff concerns, with improving MACD signaling potential reversal despite recent downtrend....

Summary: Re-entering long soon after recent cash exit at similar 501 level justified by new bullish expansions in Ireland and Bay Area overriding prior downtrend concerns, as price holds rising support near 492 with improving MACD and oversold RSI signaling bounce potential....

Summary: Stay in cash as TMO remains in a persistent downtrend below the broken 512 rising support with still-negative MACD, despite an oversold RSI of 33 and a bounce from the 492 rising trendline, without compelling new catalysts to justify quick re-entry after the recent exit amid choppy sideways action around 500....

Summary: Exit long to cash as price breaks below key rising support at 512 amid persistent downtrend and negative MACD, despite oversold RSI signaling potential bounce but lacking confirmation....

Summary: Hold long on TMO as price stabilizes above rising support at 510 with improving MACD histogram and rising STO, backed by bullish analyst targets averaging $660 signaling strong upside potential despite unrealized loss from 527 entry....

Summary: Hold long on TMO as price bounces from capitulation bottoms at 498/504 with improving MACD histogram, rising STO, analyst buy ratings and $634 PT average signaling upside despite unrealized loss from 527 entry....

Summary: Hold long on TMO amid oversold RSI 31, recent capitulation bottoms at 498/504, dividend hike to $0.47, Morgan Stanley PT $670 overweight, and rising supports near 509/493 signaling bounce potential despite drop from 527 entry....

Summary: Hold long on TMO as it bounces from $502 rising support in oversold RSI 31 post multiple capitulation signals, with bullish catalysts like 10% dividend hike, $5B buyback, Clario acquisition adding $0.45 EPS and $175M synergies, and analyst targets near $639 amid recovering life sciences demand overriding China/funding caution....

Summary: Hold long on TMO as it stabilizes above $500 rising support post-capitulation lows, with bullish catalysts like 10% dividend hike, $5B buyback, Clario acquisition EPS boost, and $639 analyst targets overriding guidance miss digestion....

Summary: Hold long; TMO stabilizes ~$511 above $500 capitulation support with RSI ~25 oversold signaling bounce potential amid $670 analyst PTs and Clario acquisition tailwinds....

Summary: Hold long as TMO bounces from capitulation lows above rising supports with oversold RSI 32, bolstered by completed $3.8B Clario acquisition funding and no fresh negatives....

Summary: Hold long as TMO stabilizes above $498 capitulation low with RSI 32 oversold, supported by rising trendline, recent large investor accumulation, and $3.8B debt for Clario acquisition amid no new negatives....

Summary: Hold long as TMO rebounds from $498 capitulation low with RSI 32 oversold, above rising $497 support trendline, bolstered by $3.8B Clario acquisition debt and no fresh negatives post-earnings miss....

Summary: Hold long as TMO rebounds from $498 capitulation low with RSI 28 oversold, bolstered by $3.8B debt for Clario buy and analyst upgrades amid digested guidance miss....

Summary: Hold long; TMO bounces +2.4% to $514 close from $498 capitulation low, RSI ~22 extreme oversold signals reversal amid institutional buys....

Summary: Hold long as price bounces off high-conviction volume capitulation at 498 low with oversold RSI 26 signaling stronger reversal bottom, bolstered by $3.8B debt for Clario buyout and analyst upgrades to $650 amid positive ratings....

Summary: Hold long as new high-conviction volume capitulation at $498 low with RSI 21 oversold signals stronger reversal bottom, bolstered by $3.8B debt offering funding Clario acquisition and analyst upgrades to $685 targets amid no fresh bearish news....

Summary: Hold long as today's high-conviction volume capitulation at $505 low with RSI 21 signals market bottom and reversal, overriding recent downside from earnings miss as Clario deal funding closes with no new bearish catalysts....

Summary: Hold long as extreme oversold RSI 22 and high-volume capitulation signal imminent reversal, with $3.8B debt offering closing today funding Clario acquisition as strong bullish catalyst despite continued post-earnings weakness....

Summary: Re-enter long immediately after recent cash exit at much lower 526 vs 542 as post-earnings guidance miss fully digested in further drop, extreme oversold RSI 25 signals imminent bounce from 522 rising support trendline, and new $3.8B debt offering for Clario acquisition provides bullish catalyst overriding prior downside concerns....

Summary: Continuing post-earnings downtrend with price breaking below supports into oversold territory but lacking reversal confirmation, compounded by fresh debt issuance for Clario acquisition raising leverage concerns amid weak 2026 guidance, justifying staying sidelined after recent exit without compelling new positives for quick re-entry....

Summary: Stay in cash as post-earnings downside from weak 2026 guidance persists without clear reversal signals or new catalysts to justify quick re-entry after recent exit on break below $550 support....

Summary: Staying in cash as the post-earnings downtrend persists with price still below broken $550 support, oversold indicators not yet signaling reversal, and no major new bullish catalysts outweighing the guidance miss risks....

Summary: Exit long to cash as post-earnings sell-off deepens with 2026 profit guidance missing estimates, price breaking below key $550 support on high volume into oversold RSI, indicating continued downside pressure despite solid Q4 beat....

Summary: Hold long; Q4 beat (EPS $6.57 vs $6.45 est., rev $12.22B vs $11.95B) with solid 2026 guide sparks dip-buy amid Buy PTs $626+.[[1]](https://ir.thermofisher.com/investors/news-events/news/news-details/2026/Thermo-Fisher-Scientific-Reports-Fourth-Quarter-and-Full-Year-2025-Results/default.aspx)[[2]](https://finance.yahoo.com/news/thermo-fisher-scientific-q4-earnings-070805745.html)...

Summary: Hold long; TMO consolidates ~$626 pre-earnings with strong buy consensus ($657 PT) and positive Zacks preview intact.[[1]](https://public.com/stocks/tmo/forecast-price-target)[[2]](https://finance.yahoo.com/news/countdown-thermo-fisher-tmo-q4-141504883.html)...

Summary: Hold long; TMO consolidates ~$630 pre-earnings with $657 avg PT from 29 analysts and Zacks beat outlook intact.[[1]](https://www.barrons.com/market-data/stocks/tmo?gaa_at=eafs&gaa_n=AWEtsqeY2n0v0bJXeBOoQMzOrZGypaCta_gkK5To7IRvdYlmMREkVv8YA6ML&gaa_sig=e8TAEcgZ3AGUMF_YtN6fu3dmJKjOM9OAmnSS5CgFXm7cmn_UBYLxsqMpVdEJ62cWV3rHhgTK_6jsSZeBz_omeQ%3D%3D&gaa_ts=6977fc83)[[2]](https://finance.yahoo.com/quote/TMO)...

Summary: Hold long; TMO powers $642 ATH on gamma squeeze volume, BofA $710 PT hike and Vanguard mega-adds cement earnings blowout path....

Summary: Hold long; TMO rips $638 ATH amid earnings countdown frenzy, institutional pile-on and Zacks beat thesis unshakeable....

Summary: Hold long; TMO blasts $635 ATH on pre-earnings FOMO, Zacks beat preview and Renaissance adds overpower any noise....

Summary: Hold long; TMO nears $632 pre-earnings ATH grind, Renaissance/Vanguard flows and Zacks #1 Strong Buy rating fuel squeeze....

Summary: Hold long; TMO tests $628 ATH on pre-earnings volume spike, institutional adds (Renaissance +) and Zacks beat odds dominate....

Summary: Hold long; TMO rips to $625+ on Nvidia collab digestion and Zacks earnings beat preview, shrugging off noise....

Summary: Re-enter long immediately after cash as Nvidia collab boosts long-term AI lab TAM, Lagarde shift internal promo/routine, PKO trim microscopic—pre-earnings dip fully digested into buy zone....

Summary: Close long to cash; after-hours slip on Nvidia tie-up despite collab, exec shake-up, PKO 24% trim warrant profit-taking pre-earnings....

Summary: Hold long; pre-earnings momentum builds with $605 test, Zacks strong buy rating and institutional stability intact....

Summary: Hold long; after-hours slip on thin volume shrugged off by Zacks earnings beat potential and $631 buy consensus....

Summary: Hold long; Q4 earnings preview strong (EPS $5.57/rev $10.57B est. Jan 28), StockInvest buy signal $613 target amid ATH test....

Summary: Hold long; stacked SMAs/green MACD/solid RS per charts, Railway Pension +174% stake to 318k shares outweigh NORTHSTAR trim....

Summary: Hold long; Robeco +233k shares (44% hike), Stevens new stake, BofA $700 PT signal strong institutional conviction....

Summary: Hold long; TMO pushes $592 on Jan 3 volume surge, Wolfe/Jefferies PTs ($680/$650) and sector rotation back healthcare leaders....

Summary: Hold long; markets kick off 2026 with Dow/S&P gains, TMO Buy consensus $631 target and technical uptrend hold firm....

Summary: Hold long; Piper Sandler upgrades to Overweight $710 PT, BlackRock Q4 +200k shares ignite fresh leg higher....

Summary: Hold long; Wolfe Research starts Outperform $680 PT, Vanguard Q4 stake hike + Vanguard flows signal institutional conviction....

Summary: Hold long; Jefferies initiates Buy $650 PT today, Swedbank/Geneos adds and PPD Alzheimer's data momentum drive post-holiday surge....

Summary: Maintaining the long position as the uptrend remains confirmed with price above rising EMA and SMA, positive MACD, no volume capitulation or immediate catalysts to exit, and targeting resistance near 598 while adhering to minimum hold periods....

Summary: Entering long on this dip in a confirmed uptrend with price above rising EMA and SMA, positive MACD, and no immediate catalysts, targeting resistance near 598 over the next few weeks. Technical indicators support this: MACD is positive at 0.8567 above its signal line, RSI at 53.22 is neutral (not overbought), STO is rising, and Bollinger Bands are narrowing but price is near the upper band, suggesting potential for continuation. No volume capitulation needed here as we're not in a downtrend, and the lack of "!" or "BOT" flags aligns with steady volume without panic selling....

Summary: Staying in cash as TMO's uptrend persists but current price near recent highs without a clear dip, bearish MACD crossover, and no strong bullish catalysts justify entry now, with next earnings around late January 2026....

Summary: Staying in cash as TMO's uptrend persists but bearish MACD crossover and recent rejection near 598 resistance suggest potential pullback, with no strong bullish catalysts or volume capitulation to justify quick re-entry after the 12/12 exit due to similar fading momentum....

Summary: Staying in cash as the trend is unclear with EMA and SMA tightly bound and price crossing them multiple times recently without volume capitulation, while technicals show neutral RSI, bearish MACD crossover, and price churning sideways near falling resistance around 569-576, offering no high-confidence long setup in this biotech stock where shorting is avoided....

Summary: Staying in cash as TMO's trend is unclear with price below both EMA and SMA, which are moving sideways without a defined uptrend or volume capitulation to justify a long entry, while resistance at 598 caps upside and no immediate catalysts support a trade....

Summary: Staying in cash as the trend is unclear with price below both EMA and SMA, recent rejection at $598 resistance, bearish MACD crossover, and no volume capitulation or strong catalysts to justify entry, while avoiding shorts on this biotech stock....

Summary: Staying in cash as the trend is unclear with price below EMA despite EMA above SMA, recent resistance rejection at 598 signaling potential further pullback to 550 support, no volume capitulation or bullish catalysts, and history of losses on premature long entries in similar choppy conditions. MACD is bearish with the line below the signal (1.3994 < 4.0423), STO is oversold but without conviction for a rebound, and RSI at 45.64 suggests neutral momentum leaning weak. There's no recent volume capitulation flagged, and the past two months lack "!" or "BOT" indicators to justify buying a dip in what could be interpreted as a downtrend pause....

Summary: Staying in cash as the uptrend persists but bearish MACD signals caution after recent rejection at 598 resistance and our quick exit on 12/12 due to fading momentum, with no new catalysts or volume capitulation to justify re-entry so soon despite a slight price recovery....

Summary: Exiting the long position in TMO as price has rejected at 598 resistance with bearish MACD crossover below signal, overbought conditions fading, and pullback toward 550 support signaling potential further downside over the next few weeks, despite intact uptrend....

Summary: Staying long in TMO as the uptrend continues with EMA above SMA and both rising, price above key 550 support despite a mild pullback, no earnings or catalysts imminent, and positive sector tailwinds from medtech demand....

Summary: Staying long in TMO as the uptrend persists with EMA above SMA and both rising, price holding above 550 support amid a pullback, no immediate catalysts or earnings, and positive medtech sector momentum from recent acquisitions and demand. No volume capitulation in the last two months, but that's not required here since we're already positioned in an uptrend. MACD is below its signal line (2.80 vs 6.68), indicating some bearish momentum, but this hasn't broken key supports, and RSI at 49 suggests neutral conditions without oversold signals to prompt an exit. STO is low at 18.7, hinting at potential rebound, and Bollinger Bands are contracting (upper 597.53, lower 561.31), often preceding volatility—likely upward given the trend....

Summary: Staying long in TMO as the uptrend continues with EMA above SMA and both rising, price pulling back but holding above key support at 550 without breakdowns or catalysts, supported by positive medtech sector trends and no near-term earnings. ...

Summary: Staying long in TMO as the overall uptrend persists with rising EMA and SMA despite the recent pullback below EMA, solid support at 550 holding, positive healthcare sector momentum from medtech demand, and no immediate catalysts or breakdowns signaling an exit after only 5 bars....

Summary: Staying long in TMO as the uptrend holds with price above rising EMA and SMA, positive fundamentals in healthcare sector, no near-term catalysts, and support at 550 intact while targeting resistance near 600-610 despite recent pullback. MACD is positive at 6.41 but below the signal at 9.6, indicating some fading momentum after the November run-up to 597.78, yet no bearish crossover invalidates the trend; RSI at 49.08 is neutral, avoiding overbought conditions, and Slow STO K/D at 36.20/52.25 suggests room for recovery without immediate downside pressure....

Summary: Staying long in TMO as the uptrend persists with price above rising EMA and SMA, positive MACD momentum despite recent pullback, no immediate catalysts or earnings, and targeting resistance near 610 while support at 550 holds firm....

Summary: Staying long in TMO as the uptrend holds with price above rising EMA and SMA, positive overall momentum despite minor pullback, no immediate earnings or catalysts, and targeting resistance near 610 while support at 550 remains intact. The chart shows a confirmed uptrend: EMA at 570.60 is above SMA at 552.50, price at 581.20 is above both, and both averages are trending upward without frequent crossings or sideways movement in the past month. MACD is at 9.11 with signal at 11.06, indicating a recent bearish crossover, but the overall trend remains positive with no breakdown below key levels; RSI at 55.97 is neutral, and Slow STO K/D at 57.69/67.33 suggests some overbought unwinding but not extreme....

Summary: Staying long in TMO as the position is only one bar old, uptrend remains confirmed with price above rising EMA and SMA, positive MACD overall trend despite minor pullback, no immediate earnings or catalysts, and targeting resistance near 610 with support at 550 holding firm....

Summary: Entering long on this dip in a confirmed uptrend with price above rising EMA and SMA, positive MACD momentum, and no immediate catalysts or overbought signals, targeting resistance near 610 over the next few weeks....

Summary: Exiting the long position in TMO as price shows rejection near resistance at 598 with overbought RSI above 70, bearish MACD divergence, and fading momentum after recent highs, locking in gains while uptrend remains but no fresh catalysts support holding....

Summary: Holding the long position in TMO as the uptrend persists with price above rising EMA and SMA, recent breakout momentum, no breach of support near 567-573, and targeting higher resistance around 610 amid positive sector sentiment and no near-term earnings....

Summary: Holding the long position in TMO as the uptrend continues with price above rising EMA and SMA, positive momentum from recent highs, no break below support near 566-570, and targeting resistance around 600-610 amid favorable biotech sector news and no immediate earnings....

Summary: Holding the long position in TMO as the uptrend persists with price above rising EMA and SMA, positive MACD despite recent dip, no break below support at 566-570, and targeting resistance near 600 amid stable biotech sector and no immediate catalysts....

Summary: Holding the long position in TMO as the uptrend continues with price above rising EMA and SMA, positive MACD momentum, no break below support near 566-570, and targeting resistance around 600 amid favorable biotech sector trends and no immediate catalysts....

Summary: Holding the long position in TMO as the uptrend persists with price above rising EMA and SMA, positive MACD momentum building, no break below support at 566, and aiming for resistance near 600 amid stable biotech trends and no near-term catalysts....

Summary: Continuing to hold the long position in TMO as the uptrend remains intact with price above rising EMA and SMA, positive MACD despite recent pullback, no breakdowns below key support near 566, and aiming for resistance around 600 supported by strong biotech sector trends and no immediate catalysts....

Summary: Holding long in TMO as the uptrend persists with price above rising EMA and SMA, positive MACD, no breakdowns below key supports near 566, and targeting resistance around 600 amid favorable biotech sector momentum....

Summary: Holding long in TMO as the uptrend remains intact with EMA above SMA, price above both and moving upward, positive MACD momentum despite recent pullback, no breakdowns or negative catalysts, targeting resistance near 600 over the next few weeks. The pullback from the entry at 588.02 to 569.7 appears as a healthy dip within the uptrend, supported by rising support trendlines around 569-570, and no volume capitulation suggesting the end of upside. MACD is positive at 13.23 but below signal at 14.86, indicating fading momentum short-term, yet the histogram remains constructive without divergence; STO at 69.46 is neutral, not overbought. RSI at 57.90 shows room to run without exhaustion....

Summary: Holding long in TMO despite minor pullback from 588.02 entry to 582.14 as uptrend persists with EMA above SMA, price above both and moving upward, positive MACD momentum, and no breakdowns or catalysts, targeting resistance near 610 over the next few weeks....

Summary: Holding long in TMO as the uptrend persists with EMA above SMA, price above both and breaking recent highs toward resistance at 610, supported by positive MACD and no immediate catalysts or breakdowns after the entry at 588.02 despite minor pullback to 587.69....

Summary: Entering long on continued uptrend strength with price breaking above prior resistance near 576, positive MACD momentum, and no immediate catalysts or overbought signals warranting caution, targeting higher levels around 600 over the next few weeks while justifying quick re-entry since the 11/4 exit due to the sustained breakout and lack of pullback invalidating previous rejection concerns....

Summary: Price is at overbought highs near falling resistance at 585 with bearish MACD crossover and no volume capitulation, indicating risk of pullback in this uptrend despite strong fundamentals; staying in cash to await a dip for better entry. Recent bars reveal a strong rally from October lows around 462 to the current close at 584.54, testing the falling resistance trendline at 585.85 (strength 2.2655 with 3 bounces), which has historically capped advances, as seen in similar rejections in September and October data points. RSI at 73.62 signals overbought conditions, STO K at 94.15 is extremely elevated, and MACD (15.0353) is below its signal line (15.3897), confirming a bearish crossover that often precedes pullbacks in this stock's history, like the drop after the 11/4 exit at 565 near 576 resistance....

Summary: Staying in cash as TMO is testing falling resistance at $583.66 with overbought STO at 91 and MACD showing fading momentum near highs, mirroring past rejections leading to pullbacks, despite uptrend and no immediate catalysts....

Summary: The stock remains in a confirmed uptrend but is overbought with STO above 80, MACD below its signal line indicating weakening momentum, and price rejecting at the falling resistance trendline around $577, prompting caution to wait for a dip for better long entry rather than chasing near highs....

Summary: The stock remains in a confirmed uptrend with price above rising EMA and SMA, but after recent exit on rejection near falling resistance at 576 with bearish MACD crossover and overbought STO, current levels near 566 offer poor risk/reward for immediate re-entry without a deeper dip or new bullish catalyst, so staying in cash to avoid whipsaw and wait for better setup....

Summary: Staying in cash as the stock remains near falling resistance at 576 with persistent bearish MACD crossover and overbought STO, lacking a clear dip in the uptrend for high-confidence long re-entry soon after the 11/4 exit, while shorting is avoided for this biotech stock....

Summary: Exiting the long position in TMO as price shows rejection near falling resistance at 576 with MACD bearish crossover below signal, overbought STO at 80, and no fresh bullish catalysts to push higher, locking in near break-even after minimum hold while uptrend remains but momentum fades....

Summary: Continuing the long position in TMO as the uptrend persists with price above rising EMA and SMA, positive MACD momentum, no bearish catalysts or resistance breaches, and targeting 579-585 while monitoring pullbacks....

Summary: Continuing the long position in TMO as the uptrend remains strong with price above rising EMA and SMA, positive MACD despite minor signal crossover, and no compelling bearish catalysts or resistance breaches yet, targeting 579-585 while monitoring for sustained weakness. Volume has been supportive during advances, and there's no sign of capitulation or breakdown below key supports like the rising trendline at ~537; instead, recent dips have found buyers, as seen in the bounce from 556 to 569....

Summary: Continuing the long position in TMO as the uptrend persists with price above rising EMA and SMA, positive MACD, and sustained bullish momentum from recent earnings beat, targeting resistance near $579-$585 while weathering minor pullbacks....

Summary: Continuing the long position in TMO as the uptrend remains strong with price above rising EMA and SMA, positive MACD divergence, and bullish momentum from recent earnings beat targeting resistance around $579-$585, while ignoring minor pullbacks without breakdown....

Summary: Continuing the long position in TMO as the uptrend persists with price above rising EMA and SMA, positive MACD, and post-earnings momentum aiming for resistance near $579, despite a minor pullback to $555.76. MACD remains bullish at 18.46 above the signal line at 17.26, and RSI at 63.51 indicates room for upside without overbought conditions. The recent pullback from $572.50 to $555.76 appears as a healthy dip within the uptrend, testing support near the rising trendline around $526.60 (last tested 20 bars ago with strength 0.16775), but price held above it without breaking lower for 5 consecutive bars, suggesting no invalidation....

Summary: Continuing the long position in TMO as the uptrend remains intact with price above rising EMA and SMA, positive MACD, and sustained post-earnings momentum targeting resistance near $579, despite a minor pullback....

Summary: Continuing the long position in TMO's strong uptrend with price above rising EMA/SMA, bullish MACD divergence, overbought RSI but sustained momentum post-earnings, targeting resistance at $579 amid positive healthcare sector trends and no near-term catalysts....

Summary: Continuing the long position in TMO's confirmed uptrend post-earnings gap-up, with price above rising EMA and SMA, bullish MACD, and momentum targeting resistance near $579, supported by positive sector news and no immediate catalysts....

Summary: Entering long on post-earnings strength in a confirmed uptrend with price above EMA and SMA, bullish MACD, and positive momentum targeting higher resistance near $579 over the next few weeks, justified by the recent earnings beat and gap-up breakout providing new bullish catalyst since the precautionary exit on 10/20....

Summary: Staying in cash due to upcoming earnings on 10/22/2025, with the chart showing an uptrend but no high-confidence entry setup without risking volatility, and no other immediate catalysts identified....

Summary: Exiting the long position ahead of earnings on 10/22/2025 to avoid volatility, as it doesn't qualify for holding through based on historical surprises, while the uptrend remains intact with price above EMA/SMA and positive MACD, but no other catalysts justify the risk....

Summary: Holding the long position as the uptrend continues with price above EMA and SMA, positive MACD, no breakdowns, and earnings on 10/22/2025 still more than 3 days away without qualifying to hold through....

Summary: Holding the long position as the uptrend persists with price above EMA and SMA, positive MACD momentum, no breakdowns near resistance, and earnings on 10/22/2025 still over 3 days away without qualifying to hold through based on historical reactions....

Summary: Holding the long position as the uptrend remains intact with price above EMA and SMA, positive MACD, no immediate catalysts or breakdowns, and sufficient time before 10/22/2025 earnings to capture more upside....

Summary: TMO shows strong institutional buying, a moderate buy rating with a $585 target, and expected earnings growth, making it wise to hold the long position....

Summary: Continuing to hold the long position as technicals remain supportive with price above EMA and SMA, positive MACD, and sufficient time before earnings to capture more upside, despite recent pullback....

Summary: Holding the long position as the uptrend remains intact with price above EMA and SMA, positive MACD, no bearish reversals, and time before earnings on 10/22/2025 allows for further upside potential....

Summary: Holding the long position as the uptrend continues with price above EMA and SMA, positive MACD momentum, no bearish reversal signals, and sufficient time before next earnings on 10/22/2025 for potential further upside....

Summary: Holding the long position as the uptrend persists with price above EMA and SMA, bullish MACD crossover, no clear bearish reversal on the chart, and next earnings on 10/22/2025 providing room for further gains before considering an exit closer to the date....

Summary: Holding the long position as the uptrend remains strong with price above EMA and SMA, bullish MACD, no bearish reversal signals, and next earnings on 10/22/2025 still weeks away allowing for further upside potential....

Summary: Holding the long position as the strong uptrend continues with price well above EMA and SMA, bullish MACD crossover and high volume supporting the recent gap up, no immediate resistance or bearish catalysts, and next earnings on 10/22/2025 still allowing for minimum hold duration. Momentum indicators are supportive: MACD at 12.81 above its signal line at 4.78 indicates strong bullish momentum, RSI at 71.79 is overbought but not extreme enough to signal reversal in this context, and Slow STO K at 85.56 with D at 65.06 suggests continued upward pressure. Volume on the gap day was high at over 6 million shares, validating the breakout, and subsequent days show sustained buying interest without capitulation signals....

Summary: Holding the long position as the strong uptrend persists with price above EMA and SMA, bullish MACD, high volume gap confirmation, and no near-term resistance or catalysts demanding exit, with next earnings on 10/22/2025....

Summary: Holding the long position as the recent gap up on high volume confirms a strong uptrend with price above both EMA and SMA, bullish MACD, and no immediate resistance or catalysts warranting an exit, targeting further upside over the coming weeks with next earnings on 10/22/2025....

Summary: Entering long on the massive gap up breakout above resistance on high volume, confirming a new uptrend with bullish MACD crossover and positive momentum, targeting higher levels over the next few weeks despite recent losses, with next earnings on 10/22/2025....

Summary: Staying in cash due to unclear trend with EMA below SMA despite price above both, recent price crossings of averages, no volume capitulation, and repeated losses on prior longs from pullbacks, while awaiting confirmation of uptrend for a high-confidence entry targeting resistance at $496.5....

Summary: Staying in cash as TMO is in a downtrend with price below both EMA and SMA, no volume capitulation to justify a long entry, and as a biotech stock it cannot be shorted, while recent pullbacks show risk of further downside without clear reversal signals....

Summary: Exiting the long position as price remains below both EMA and SMA in an unclear trend with bearish MACD, no volume capitulation, and failure to rebound toward 496 resistance, locking in the loss to await a clearer setup. MACD is bearish at -2.94, below the signal line, and RSI at 42.52 suggests neutral to oversold conditions but no strong reversal signal. Volume on the latest bar is average at 1.23M, with no capitulation flagged in the past month to support a bottom....

Summary: Holding the long position as the chart shows price stabilizing near support after a pullback in an unclear trend with EMA slightly above SMA, no volume capitulation, bearish MACD but potential rebound to 496 resistance, and minimum hold period not yet met despite recent dip below key levels....

Summary: Holding the long position as the minimum hold period hasn't been met yet, despite price dipping below key support at 472 and both EMA/SMA amid unclear trend signals, with no volume capitulation and bearish MACD suggesting caution but potential for rebound targeting 496 resistance....

Summary: Holding the long position as price holds above SMA near key support at 472 without confirmed breakdown, EMA remains above SMA suggesting potential uptrend continuation, targeting resistance at 496 over the coming weeks despite bearish MACD and recent pullback....

Summary: Holding the long position as the uptrend persists with EMA above SMA, price near key support without breaking down, targeting resistance at $496, despite recent pullback and bearish MACD, with no immediate catalysts or volume capitulation signaling reversal. Price closed at $475.47, above SMA ($471.46) but below EMA ($478.19), indicating a pullback in an uptrend rather than a downtrend shift, as there's no sustained price below both averages or volume capitulation to confirm a reversal. Technicals like RSI at 47.71 suggest neutral momentum, not oversold, while MACD (0.8589 below signal 3.2219) shows bearish divergence, but this was noted in the entry rationale and hasn't worsened dramatically. Bollinger Bands are contracting (upper $496.81, lower $471.74), pointing to a rangebound phase, with price near the lower band but holding above recent support around $470-472 from mid-September lows....

Summary: Holding the long position as the uptrend remains intact with price above both EMA and SMA, no frequent crossings, and targeting resistance at $496, despite bearish MACD, with no immediate earnings or catalysts....

Summary: Entering long on this bounce back above EMA in a confirmed uptrend after a brief pullback, with price above both EMA and SMA, no frequent crossings, positive MACD momentum, and no immediate earnings or catalysts, targeting resistance near $496 over the next few weeks while avoiding quick re-entry pitfalls from yesterday's exit justified by the sharp recovery and improved technicals....

Summary: Exiting the long position as price has broken below the EMA in an unclear trend with bearish MACD crossover and no volume capitulation to support a rebound, locking in the loss to avoid further downside while awaiting a clearer setup....

Summary: Maintaining the long position as the uptrend continues with EMA above SMA and price above both, recent pullback finding support near $470 without breakdown, and no imminent catalysts or volume capitulation signaling reversal, despite minor unrealized loss....

Summary: Maintaining the long position as the overall uptrend from July earnings persists despite the recent pullback to support near $472, with EMA still above SMA, no breakdowns or volume capitulation signaling reversal, and no major catalysts imminent....

Summary: Maintaining the long position as the uptrend persists with EMA above SMA and price above both, no volume capitulation or breakdowns below key supports, recent pullback from resistance at $496.5 appears as a healthy dip without bearish reversal signals, and no earnings or major catalysts in the next 3 days....

Summary: Maintaining the long position as the uptrend continues with EMA above SMA and price above both, recent bounce from support showing strength, approaching resistance at $496.5 but no immediate sell signals after short hold, and no earnings or catalysts in next 3 days....

Summary: Maintaining the long position as the uptrend persists with EMA above SMA and price near support levels showing historical bounce potential, no volume capitulation or breakdowns, and no immediate catalysts warranting exit after only a short hold....

Summary: Maintaining the long position as the uptrend remains intact with price above EMA and SMA, despite a minor pullback, supported by no immediate catalysts or breakdowns and historical resilience after dips....

Summary: Entering long at $485.7 on this dip in a confirmed uptrend with price above both EMA and SMA, following a pullback from resistance near $496.5, offering a better entry price than the recent exit at $492.6; re-entering soon justified by the sharp price correction providing improved risk/reward while technicals remain supportive....

Summary: Exiting the long position as price hit new highs near resistance at $496.5 but closed lower with rejection, MACD showing bearish momentum below signal line, and uptrend intact but overbought conditions suggesting potential pullback, locking in gains after minimum hold period....

Summary: Holding the long position as the uptrend continues with price above EMA and SMA, approaching resistance at $496.5 but not yet reached, positive MACD momentum building, no earnings or catalysts within 3 days, and stable sector without major bearish news....

Summary: Holding the long position as the uptrend persists with price above EMA and SMA, positive MACD despite recent pullback, no immediate earnings or catalysts, and stable healthcare sector fundamentals without bearish news. Technicals are prioritized, and while there's a minor pullback from recent highs near $500, this appears as a healthy dip in an ongoing uptrend rather than a reversal, supported by no volume capitulation and price holding above key support levels like $458.85 from the rising trendline....

Summary: Holding the long position as the uptrend continues with price above EMA and SMA, positive MACD momentum, no near-term earnings or catalysts, and stable fundamentals in healthcare amid no major bearish news....

Summary: Continuing to hold the long position as the uptrend persists with price above both EMA and SMA, positive momentum toward $496.5 resistance, no earnings or catalysts within 3 days, and stable healthcare sector amid no major negative news....

Summary: Holding the long position as the uptrend continues with price above EMA and SMA, positive MACD, no upcoming earnings or major catalysts within 3 days, and potential to approach $496.5 resistance again amid stable fundamentals in healthcare diagnostics....

Summary: Holding the long position as the uptrend persists with price above EMA and SMA, positive MACD, no imminent earnings or catalysts, and potential upside to retest $496.5 resistance amid stable healthcare sector sentiment. There have been no frequent crossings of EMA/SMA or price in the past month (less than 2 times), and no volume capitulation flagged, so the trend remains clear and supportive of longs. The MACD is positive at 12.20, though below its signal line at 13.20, indicating momentum is still bullish but waning slightly; however, this doesn't override the trend. RSI at 57.85 is neutral, avoiding overbought territory, and Slow STO K/D at 77.93/83.88 suggests continued strength without immediate reversal risk. Support levels are noted at $390.50 (strong, multiple bounces) and $401.45, providing a safety net, while resistance at $496.50 aligns with prior highs where we exited profitably before—current price is below this, offering room for upside without buying at the top of the range....

Summary: Holding the long position as the uptrend remains confirmed with price above EMA and SMA, positive MACD despite recent pullback, no earnings or catalysts within 3 days, and potential for retest of $496.5 resistance after dip....

Summary: Holding the long position as the uptrend is confirmed with price above EMA and SMA, positive MACD, recent breakout above $496.5 resistance on 8/22, and no immediate catalysts or trend reversals warranting an exit after only 2 bars....

Summary: Holding the long position as the uptrend remains confirmed with price above EMA and SMA, positive MACD, and recent breakout above resistance at $496.5 on increasing volume, targeting further upside over the next few weeks....

Summary: Entering long on this dip in a confirmed uptrend after pulling back from resistance, with price above EMA and SMA, positive MACD, and a better entry price than recent exit. We exited the prior long yesterday at 494.81 near the $496.5 resistance with overbought STO, but today's pullback to 484 provides a much better entry price (about 2% lower) and a changed circumstance as it failed to hold above resistance but remains supported above key levels like $401.45 and rising trendlines around $483-492. No volume capitulation flagged recently, and the trend isn't unclear with infrequent crossings in the past month....

Summary: TMO is approaching key resistance at $496.5 with overbought STO and failure to sustain above it, prompting exit of the long position at $495.22 for profit realization before potential pullback, no upcoming catalysts....

Summary: TMO continues in a strong uptrend with price breaking above $496 resistance on positive momentum, no upcoming catalysts or exit signals, holding the long position from $466.71 for further upside potential....

Summary: TMO remains in a clear uptrend with price above both EMA and SMA, no exit signals or upcoming catalysts, holding the long position from $466.71 as it approaches $496 resistance with positive momentum....

Summary: TMO continues in a strong uptrend with price above EMA and SMA, no exit signals like volume capitulation or catalysts, holding the profitable long from $466.71 as it nears $496 resistance....

Summary: TMO remains in a clear uptrend with price above both EMA and SMA, holding the long position from $466.71 as it approaches $496 resistance without any exit signals like volume capitulation or upcoming catalysts....

Summary: TMO continues in a strong uptrend with price above EMA and SMA, climbing towards $496 resistance after post-earnings gap, with no catalysts or volume capitulation signaling an exit yet....

Summary: TMO remains in a clear uptrend with price above both EMA and SMA, rebounding strongly from recent support around $450 toward resistance near $496 after the post-earnings gap, with no volume capitulation or immediate catalysts suggesting an exit....

Summary: TMO continues in a clear uptrend with price above both EMA and SMA, rebounding from recent support near $450 toward resistance around $477 after a post-earnings gap up, with no immediate catalysts or earnings to disrupt the hold....

Summary: TMO remains in a clear uptrend with price above both EMA and SMA after a strong post-earnings gap up, pulling back to support near $450 before rebounding toward resistance around $477, supported by positive Q2 results and no near-term catalysts, suggesting potential for further upside over the next few weeks....

Summary: Despite a recent pullback, TMO maintains an uptrend with price above both EMA and SMA, supported by strong Q2 earnings beats and positive institutional activity like Parnassus Investments adding shares, suggesting potential rebound toward $480 resistance over the next few weeks....

Summary: Despite the recent pullback, TMO remains in a clear uptrend with price above both EMA and SMA, bolstered by strong Q2 earnings performance including revenue and EPS beats, and positive sentiment from sources like Seeking Alpha highlighting undervaluation and growth in pharma/biotech segments, positioning for a rebound toward $480 resistance over the coming weeks....

Summary: The stock maintains a clear uptrend with price above both EMA and SMA, recent consolidation holding above key supports post-earnings beat, and positive momentum from Q2 results suggesting further upside toward $480 resistance over the coming weeks....

Summary: The stock remains in a clear uptrend with price above both EMA and SMA, recent pullback finding support without breaking key levels, and positive Q2 earnings momentum supporting further upside toward resistance around $482 over the next few weeks....

Summary: The stock maintains a clear uptrend with price above both EMA and SMA, recent earnings beat and positive analyst sentiment supporting continued upside despite minor pullback, justifying holding the long position for at least another week targeting resistance near $482....

Summary: The stock remains in a clear uptrend with price above both EMA and SMA, supported by recent Q2 earnings beat and positive analyst updates, justifying holding the long position for further upside potential over the coming weeks....

Summary: The stock maintains a strong uptrend with price above EMA and SMA, supported by positive Q2 earnings beat, raised FY2025 guidance, and bullish momentum from recent highs, justifying continued holding for further upside over the next few weeks....

Summary: The stock remains in a strong uptrend post-earnings breakout with price above both EMA and SMA, continued positive momentum from recent highs, and supportive news on innovations and raised guidance, suggesting holding for further upside over the coming weeks....

Summary: Continuing strong uptrend post-earnings beat with positive analyst updates and no immediate catalysts to disrupt momentum....

Summary: The stock remains in a strong uptrend post-earnings breakout with positive FY2025 guidance and analyst upgrades supporting further upside over the coming weeks....

Summary: Continue holding the long position as the uptrend remains intact post-earnings beat, with price above EMA and SMA, and positive guidance suggesting further upside over the coming weeks....

Summary: The stock gapped up significantly on strong Q2 earnings beat with revenue and EPS exceeding estimates, breaking out of a downtrend on high volume into a clear uptrend, suggesting further upside over the next few weeks....

Summary: Exiting the short position due to upcoming earnings on 7/23/2025 to avoid holding through potential volatility, as the trend has shifted to uptrend with price above both EMA and SMA, and no strong bearish catalysts justify the risk....

Summary: The stock is in a sustained downtrend under a falling resistance trendline at $429, with recent rejection at $434 and bearish MACD crossover, suggesting further downside to support at $390 for a favorable risk/reward short setup holding weeks....